Fulcrum Therapeutics Inc.
Cambridge‑based clinical‑stage biopharma targeting rare genetic diseases. Lead candidates: pociredir (Phase 1b for sickle cell/β‑thalassemia) and losmapimod (Phase 2b for facioscapulohumeral muscular dystrophy). Partnerships with MyoKardia, Sanofi, CAMP4 drive development.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 45
- HQ: Cambridge
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.